캘리포니아의 골수섬유증 임상 시험
골수섬유증 관련 연구 22개가 캘리포니아 내 여러 지역에서 참여자를 모집하고 있습니다.
캘리포니아의 도시
- Baldwin Park연구 10개
- Mountain View연구 7개
- Irvine연구 6개
- Los Angeles연구 6개
- Sacramento연구 4개
- Orange연구 3개
- San Diego연구 3개
공식 연구 텍스트(영어)
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- City of Hope-Lennar Foundation Cancer Center, Irvine
- Usc Norris Comprehensive Cancer Center, Los Angeles
- UCLA Medical Hematology & Oncology, Los Angeles
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07441694A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Stanford Cancer Institute, Palo Alto
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06343805A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Los Angeles Cancer Network, Glendale
- Cancer and Blood Specialty Clinic, Whittier
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT07623161A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
- UCLA Ronald Reagan Medical Center, Los Angeles
- University of California, Davis Comprehensive Cancer Center, Sacramento
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT07469891A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute Palo Alto, Palo Alto
- 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06661915A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
- Site US11, Duarte
- Site US25, Irvine
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT07849231Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT07281781CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
피험자 모집 중2상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06059391A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
피험자 모집 중1상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT07020533Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- City of Hope - Duarte, Duarte
- City of Hope - Lennar, Irvine
- UCLA, Los Angeles
- 외 1개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT05320198Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- UC Davis Health, Sacramento
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT05423691A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- City of Hope, Duarte
- University of Southern California, Los Angeles
- Hoag Family Cancer Institute, Newport Beach
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04176198TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
피험자 모집 중1상
18세 ~ 80세 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT07302776A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Stanford University, Palo Alto
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07008118A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
- City of Hope Center, Duarte
- UC Davis Comprehensive Cancer Center, Sacramento
- UC San Diego Moores Cancer Center, San Diego
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 20. 업데이트됨 · NCT07250646A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- City of Hope Medical Center, Duarte
- Stanford Cancer Institute, Palo Alto
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 17. 업데이트됨 · NCT06034002Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 3. 27. 업데이트됨 · NCT06063486A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
피험자 모집 중2상
18세 ~ 66세 · 모든 성별 · 2026. 3. 17. 업데이트됨 · NCT06859424An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
- University of California, Irvine, Irvine
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 3. 10. 업데이트됨 · NCT05123365A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- City of Hope - Duarte Main Site, Duarte
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 12. 업데이트됨 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- 외 3개
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UC San Diego Moores Cancer Center, La Jolla
- UCLA Hematology/Oncology Clinic - Los Angeles, Los Angeles
- Scripps Health, Prebys Cancer Center, San Diego
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT06479135ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.